Mary Wheeler Email and Phone Number

BioRock Ventures is a VC fund investing seed amounts into biopharma startups. Seed-sized investments into private life science companies developing novel FDA regulated therapeutic drugs. Angel, Seed, Series A-- pre-IPO/M&A. All disease areas, all stages, all therapeutic modalities.

per AngelList Syndicate Lead "GP" Performance to date: DPI 2X MOIC 4X IRR 38% (33% net)

Strategy (corporate, business model and financing), Deal Negotiations, Contracts, Business Development, Financial Valuation, Scientific and Business Evaluation, Board level communications and external outreach.

The Johnson & Johnson California Innovation Center in Menlo Park covers all early stage (phase 2a - discovery) regional deal making for J&J companies across pharmaceutical core areas Oncology, CNS, Infectious Diseases &Vaccines, Immunological Disorders and Cardiometabolic Diseases as well as Consumer and Medical Devices/Diagnostics. I was involved in search, evaluation, relationships and negotiations for licensing, research collaborations and M&A in these areas. I also handled angel/seed funding/investing for New Company formation. For more information, visit www.jnjinnovation.com.New Company Formation and Investing: First money in, team and company formation* Vaxcyte [SutroVax], Vaccines via cell free synthesis -- https://vaxcyte.com/* 4D Molecular Therapeutics, Gene Therapy -- http://www.4dmoleculartherapeutics.com/

Focused on M&A, late stage licensing -predominantly Phase 2 Phase 3 and marketed branded therapeutics in-licensing and M&A of VC funded companies across all therapeutic areas- and 1 year in the strategy group at Forest. Forest was acquired by Actavis in 2014.

Founding team. 4 person therapeutics startup in the Boston area- acquired.